Sarcopenic
Conditions
Interventions
Control group:Oral administration of placebo at the same dosage as the experimental group
Experimental group:Oral administration of methylcobalamin tablets 1 mg, three times a day
Sponsors
The Second Hospital University of South China
Eligibility
Sex/Gender
Male
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Male aged 60 years or older (inclusive of the cutoff value) with independent ambulation ability; 2.Meeting the diagnostic criteria for sarcopenia (according to the 2019 Edition of the Asian Working Group for Sarcopenia Consensus on Diagnosis and Treatment): presence of decreased muscle strength (grip strength: male < 28 kg), reduced appendicular skeletal muscle mass (male < 7.0 kg/m^2, measured by dual-energy X-ray absorptiometry) and/or impaired physical function (6-meter gait speed < 1.0 m/s); 3.Stable health status; 4.Voluntarily agreeing to participate in the study and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Failure to meet the aforementioned diagnostic criteria and inclusion criteria; 2.History of allergy to methylcobalamin or any excipients in the formulation; 3.Engagement in work related to mercury and its compounds; 4.Presence of muscle disorders that may affect muscle mass and function, such as Duchenne muscular dystrophy, polymyositis, and myotonic dystrophy; 5.Other diseases that may affect muscle mass and function, such as vitamin B12 deficiency; 6.Resting systolic blood pressure > 200 mmHg or resting diastolic blood pressure > 100 mmHg; 7.Severe cardiac diseases: moderate to severe aortic stenosis, acute pericarditis, acute myocarditis, myocardial infarction, and uncontrolled arrhythmia; 8.History of acute stroke within the past 2 years; 9.Severe airway obstruction; 10.Lower limb fracture within the past 1 year or upper limb fracture within the past 6 months; 11.Hypercalcemia (corrected albumin serum calcium > 2.60 mmol/L); 12.Active malignant tumor; 13.Stage 4-5 chronic kidney disease; 14.Comorbidity of mental illness or moderate to severe cognitive impairment; 15.Long-term immobilization; 16.Other diseases that may interfere with the assessment of muscle mass, muscle strength, and physical function; 17.Inability to cooperate with treatment due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grip strength; | — |
Secondary
| Measure | Time frame |
|---|---|
| Five-Times Sit-to-Stand Test;4-Meter Gait Speed Test;Standing Balance Test;6-Minute Walk Test;Appendicular Skeletal Muscle Mass Index;Four-Stage Balance Test;Short Physical Performance Battery Score; | — |
Countries
China
Contacts
Public ContactWang Jianping
The Second Hospital University of South China
Outcome results
None listed